• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4: Rothberg Jonathan M was granted 1,242,096 shares and was granted 15,055,288 units of Class B Common Stock

    12/23/21 9:45:20 PM ET
    $HCAQ
    Finance
    Get the next $HCAQ alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    ROTHBERG JONATHAN M

    (Last) (First) (Middle)
    C/O HYPERFINE, INC.
    530 OLD WHITFIELD STREET

    (Street)
    GUILFORD CT 06437

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Hyperfine, Inc. [ HYPR ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    12/22/2021
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Class A Common Stock 12/22/2021 A 104,074 A (1)(2) 104,074 D
    Class A Common Stock 12/23/2021 A 16,483(3) A $0.00 120,557 D
    Class A Common Stock 12/22/2021 A 585,737 A (4) 585,737 I 2012 JMR Trust Common, LLC(5)
    Class A Common Stock 12/22/2021 A 440,295 A (6) 440,295 I 23rd Century Capital LLC(5)
    Class A Common Stock 12/22/2021 A 95,507 A (7) 95,507 I By Bonnie E Gould Rothberg MD(5)
    Class B Common Stock 12/22/2021 A 14,236,538 A (8) 14,236,538 I By 4C Holdings I, LLC(5)
    Class B Common Stock 12/22/2021 A 818,750 A (9) 818,750 I By 4C Holdings V, LLC(5)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) $3.27 12/22/2021 A 982,500 (10) 04/14/2031 Class A Common Stock 982,500 (11) 982,500 D
    Explanation of Responses:
    1. In connection with the closing of the transactions contemplated by the Business Combination Agreement, dated as of July 7, 2021, by and among HealthCor Catalio Acquisition Corp. ("HealthCor"), Optimus Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of HealthCor ("Merger Sub I"), Optimus Merger Sub II, Inc., a Delaware corporation and wholly owned subsidiary of HealthCor ("Merger Sub II"), Hyperfine, Inc., a Delaware corporation ("Hyperfine"), and Liminal Sciences, Inc.,
    2. a Delaware corporation ("Liminal"), pursuant to which Merger Sub I merged with and into Hyperfine (the "Hyperfine Merger"), with Hyperfine surviving the Hyperfine Merger as a wholly owned subsidiary of HealthCor, and Merger Sub II merged with and into Liminal (the "Liminal Merger" and, together with the Hyperfine Merger, the "Mergers"), with Liminal surviving the Liminal Merger as a wholly owned subsidiary of HealthCor (which changed its name to "Hyperfine, Inc.", the "Issuer"), these shares were received in exchange for 275,700 shares of Hyperfine Series B preferred stock and 76,739 shares of Liminal Series A-2 preferred stock.
    3. Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in equal annual installments over three years beginning on December 23, 2022, subject to Dr. Rothberg's continued service through the applicable vesting date.
    4. Received in connection with the Mergers in exchange for 1,403,701 shares of Hyperfine Series B preferred stock and 701,700 shares of Liminal Series A-2 preferred stock.
    5. Dr. Rothberg is the sole manager of 4C Holdings I, LLC, 4C Holdings V, LLC and 2012 JMR Trust Common, LLC. Dr. Rothberg is the spouse of Bonnie E. Gould Rothberg MD and Dr. Rothberg's son is the manager of 23rd Century Capital LLC. Dr. Rothberg disclaims beneficial ownership of the shares held by his spouse and 23rd Century Capital LLC.
    6. Received in connection with the Mergers in exchange for 1,344,413 shares of Hyperfine Series B preferred stock.
    7. Received in connection with the Mergers in exchange for 291,625 shares of Hyperfine Series B preferred stock.
    8. Received in connection with the Mergers in exchange for 22,500,000 shares of Hyperfine Series B preferred stock and 38,239,355 shares of Liminal Series A-1 preferred stock.
    9. Received in connection with the Mergers in exchange for 2,500,000 shares of Hyperfine Series A preferred stock.
    10. The shares underlying this option vested and became exercisable on December 15, 2021.
    11. Received in connection with the Mergers in exchange for a stock option to acquire 3,000,000 shares of Hyperfine common stock for $1.07 per share.
    /s/ John P. Condon, Attorney-in-Fact 12/23/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $HCAQ alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HCAQ

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $HCAQ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Hc Sponsor Llc converted options into 5,534,000 shares and was granted 1,000,000 shares

    4 - Hyperfine, Inc. (0001833769) (Issuer)

    12/27/21 9:10:51 PM ET
    $HCAQ
    Finance

    SEC Form 4: Hughes Mark A. was granted 19,615 shares

    4 - Hyperfine, Inc. (0001833769) (Issuer)

    12/23/21 9:46:46 PM ET
    $HCAQ
    Finance

    SEC Form 4 filed by Siddiqui Khan

    4 - Hyperfine, Inc. (0001833769) (Issuer)

    12/23/21 9:46:01 PM ET
    $HCAQ
    Finance

    $HCAQ
    SEC Filings

    View All

    SEC Form S-4MEF filed by HealthCor Catalio Acquisition Corp.

    S-4MEF - HealthCor Catalio Acquisition Corp. (0001833769) (Filer)

    12/20/21 5:14:09 PM ET
    $HCAQ
    Finance

    SEC Form 425 filed by HealthCor Catalio Acquisition Corp.

    425 - HealthCor Catalio Acquisition Corp. (0001833769) (Subject)

    12/16/21 8:08:23 AM ET
    $HCAQ
    Finance

    SEC Form 425 filed by HealthCor Catalio Acquisition Corp.

    425 - HealthCor Catalio Acquisition Corp. (0001833769) (Subject)

    12/15/21 9:18:07 AM ET
    $HCAQ
    Finance

    $HCAQ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hyperfine Closes Business Combination with HealthCor Catalio Acquisition Corp and Liminal Sciences, Will Begin Trading under the Ticker "HYPR" on the Nasdaq Global Market

    GUILFORD, Conn., Dec. 22, 2021 /PRNewswire/ -- Hyperfine Inc., the groundbreaking medical device company that created Swoop®, the world's first FDA-cleared portable MRI system™, today announced that it has completed its business combination with HealthCor Catalio Acquisition Corp. (NASDAQ:HCAQ) ("HealthCor"), a special purpose acquisition company sponsored by leading healthcare funds HealthCor Management, L.P. and Catalio Capital Management, LP, and Liminal Sciences, Inc. ("Liminal"), a medical device development company dedicated to non-invasive measurement of key vital signs in the brain. Hyperfine will receive approximately $160 million in gross cash proceeds from the business combination

    12/22/21 12:44:00 PM ET
    $HCAQ
    Finance

    HealthCor Catalio Acquisition Corp. Reminds Shareholders to Vote in Favor of the Business Combination with Hyperfine, Inc. and Liminal Sciences, Inc.

    NEW YORK, Dec. 15, 2021 /PRNewswire/ -- HealthCor Catalio Acquisition Corp. (NASDAQ:HCAQ) ("HealthCor") reminds its shareholders to vote at the upcoming extraordinary general meeting of HealthCor's shareholders (the "Special Meeting") on December 21, 2021 to, among other matters, approve the proposed business combination with Hyperfine, Inc. ("Hyperfine") and Liminal Sciences, Inc. ("Liminal") and, in connection therewith, HealthCor's change of domicile to Delaware (the "Domestication"). The affirmative vote of a majority of the ordinary shares of HealthCor voted at the Specia

    12/15/21 8:30:00 AM ET
    $HCAQ
    Finance

    Hyperfine, Liminal Sciences, and HealthCor Catalio Acquisition Corp. Announce Effectiveness of Registration Statement for Proposed Business Combination

    GUILFORD, Conn., Nov. 29, 2021 /PRNewswire/ -- Hyperfine, Inc. ("Hyperfine"), creator of the first FDA-cleared portable magnetic resonance imaging (MRI) device, Swoop®, Liminal Sciences, Inc. ("Liminal"), a medical device development company dedicated to non-invasive measurement of key vital signs in the brain, and HealthCor Catalio Acquisition Corp. ("HealthCor"), a healthcare-focused special purpose acquisition company (SPAC), today announced that the Securities and Exchange Commission ("SEC") has declared the Registration Statement on Form S-4 in connection with the proposed business combination between the companies to be effective.

    11/29/21 7:30:00 AM ET
    $HCAQ
    Finance